ATE345339T1 - N-heterocyclische derivate als nos inhibitoren - Google Patents

N-heterocyclische derivate als nos inhibitoren

Info

Publication number
ATE345339T1
ATE345339T1 AT98906555T AT98906555T ATE345339T1 AT E345339 T1 ATE345339 T1 AT E345339T1 AT 98906555 T AT98906555 T AT 98906555T AT 98906555 T AT98906555 T AT 98906555T AT E345339 T1 ATE345339 T1 AT E345339T1
Authority
AT
Austria
Prior art keywords
heterocyclic derivatives
nos inhibitors
inhibitors
compounds
nitric oxide
Prior art date
Application number
AT98906555T
Other languages
English (en)
Inventor
Damian O Arnaiz
John J Baldwin
David D Davey
James J Devlin
Roland Ellwood Dolle Iii
Shawn David Erickson
Kirk Mcmillan
Michael M Morrissey
Michael H J Ohlmeyer
Gonghua Pan
Vidyadhar Madhav Paradkar
John Parkinson
Gary B Phillips
Bin Ye
Zuchun Zhao
Original Assignee
Berlex Lab
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlex Lab, Pharmacopeia Inc filed Critical Berlex Lab
Application granted granted Critical
Publication of ATE345339T1 publication Critical patent/ATE345339T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
AT98906555T 1997-02-19 1998-02-19 N-heterocyclische derivate als nos inhibitoren ATE345339T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80897597A 1997-02-19 1997-02-19
US2512498A 1998-02-17 1998-02-17

Publications (1)

Publication Number Publication Date
ATE345339T1 true ATE345339T1 (de) 2006-12-15

Family

ID=26699322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98906555T ATE345339T1 (de) 1997-02-19 1998-02-19 N-heterocyclische derivate als nos inhibitoren

Country Status (20)

Country Link
EP (2) EP1754703A3 (de)
JP (1) JP4495257B2 (de)
KR (1) KR20000075615A (de)
CN (1) CN1100777C (de)
AT (1) ATE345339T1 (de)
AU (1) AU732969B2 (de)
CA (1) CA2281545C (de)
CZ (1) CZ2008628A3 (de)
DE (1) DE69836422T2 (de)
DK (1) DK0968206T3 (de)
ES (1) ES2277382T3 (de)
GB (1) GB2338957B (de)
IL (1) IL131475A0 (de)
NO (1) NO321664B1 (de)
NZ (1) NZ337861A (de)
PL (1) PL335235A1 (de)
PT (1) PT968206E (de)
RU (1) RU2241708C2 (de)
SK (1) SK286779B6 (de)
WO (1) WO1998037079A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
CA2280515A1 (en) * 1997-03-11 1998-09-17 E.I. Du Pont De Nemours And Company Heteroaryl azole herbicides
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
DE19836697A1 (de) * 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6432959B1 (en) * 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
BR9917082A (pt) 1998-12-24 2001-11-06 Du Pont Pharm Co Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase
AUPQ142599A0 (en) * 1999-07-05 1999-07-29 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
US7037916B2 (en) * 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
JP2003505384A (ja) 1999-07-15 2003-02-12 ファーマコピーア，インコーポレーティッド ブラジキニンｂ１受容体アンタゴニスト
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
WO2001027108A1 (en) 1999-10-08 2001-04-19 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6462046B2 (en) * 2000-01-06 2002-10-08 Advanced Syntech, Llc Heterocycle derivatives as PPAR-gamma agonists
DE10005570A1 (de) 2000-02-09 2001-08-16 Bayer Ag Verfahren zur Herstellung von 2-Methoxyethoxy-benzolen und neue 2-Methoxyethoxy-benzylcyanide
JP2003523345A (ja) 2000-02-17 2003-08-05 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環
GB2361473C (en) 2000-03-08 2005-06-28 Microgenics Corp Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
AU2001253108A1 (en) 2000-04-03 2001-10-15 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta protein production
WO2001074783A1 (en) 2000-04-03 2001-10-11 Dupont Pharmaceuticals Company Cyclic lactams as inhibitors of a βετα protein production
CA2404273A1 (en) 2000-04-11 2001-10-18 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of a.beta. protein production
CN1386118A (zh) 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
EP2335700A1 (de) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C Virus Polymerase Inhibitoren mit heterobicylischer Struktur
WO2003026661A1 (fr) * 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
EP1430032A2 (de) * 2001-09-24 2004-06-23 Elan Pharmaceuticals, Inc. Substituierte amide für die behandlung von neurologischen erkrankungen
EP1795192A3 (de) * 2002-04-30 2008-05-07 Bayer Schering Pharma Aktiengesellschaft 1-(pyridazin-3-yl)-Imidazol Derivaten als NO-Synthase (NOS) Hemmer
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
PL375375A1 (en) * 2002-08-02 2005-11-28 Pharmacia Corporation Methods for treatment and prevention of gastrointestinal conditions
AU2003260033A1 (en) * 2002-08-29 2004-03-19 Schering Aktiengesellschaft Methods of treating acute respiratory distress syndrome
AU2003288994A1 (en) 2002-12-10 2004-06-30 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
WO2004056807A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004069829A1 (en) * 2003-01-10 2004-08-19 Pharmacopeia Drug Discovery, Inc. (2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoic acid aminoethylamid derivatives as il-8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis
US7514562B2 (en) * 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
BRPI0410870A (pt) * 2003-05-30 2006-07-04 Gemin X Biotechnologies Inc compostos trieterocìclicos, composições, e métodos para tratar cáncer ou doenças virais
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
GEP20084572B (en) 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
KR20120091276A (ko) 2004-02-20 2012-08-17 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
CA2564199A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111024A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
EP1797881B1 (de) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
NZ580450A (en) * 2004-09-17 2011-06-30 Vertex Pharma Diaminotriazole Compounds Useful as Protein Kinase Inhibitors
CA2584752A1 (en) * 2004-10-21 2006-05-04 Vertex Pharmaceuticals Incorporated Triazoles useful as inhibitors of protein kinases
AU2005312048B2 (en) 2004-11-30 2012-08-02 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
US7825256B2 (en) * 2004-12-01 2010-11-02 Kalypsys, Inc. Inducible nitric oxide synthase dimerization inhibitors
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
JP2008536844A (ja) * 2005-04-15 2008-09-11 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ニューロトロフィン類似体を用いた細胞生存促進法
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP2281901B1 (de) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Pharmazeutische anti-tumor Zusammensetzung mit Angiogeneseinhibitoren
CA2618653A1 (en) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
WO2007039581A1 (en) * 2005-10-05 2007-04-12 Nycomed Gmbh Imidazolyl-substituted diazabenzophenone compounds
CA2628146A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Salts of inducible nitric oxide synthase dimerization inhibitors
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
EP2036557B1 (de) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumorales mittel gegen schilddrüsenkrebs
CA2657227A1 (en) * 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
ES2432570T3 (es) 2006-10-04 2013-12-04 Bristol-Myers Squibb Company Derivados cíclicos como moduladores de la actividad de los receptores de quimiocinas
EP1939181A1 (de) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituierte Carboxamide und deren Verwendung für die Stimulierung der NO Synthase Expression
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
BRPI0916576A2 (pt) * 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
CN104761515B (zh) 2009-11-12 2018-03-09 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP3243515B1 (de) 2011-08-30 2019-10-16 CHDI Foundation, Inc. Kynurenin-3-monooxygenase-hemmer, pharmazeutische zusammensetzungen und verfahren zur verwendung davon
AU2012318874A1 (en) * 2011-10-06 2014-05-15 Merck Sharp & Dohme Corp. 1,3-substituted azetidine PDE10 inhibitors
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
RS61664B1 (sr) 2012-04-24 2021-04-29 Vertex Pharma Inhibitori dna-pk
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
SI3424920T1 (sl) 2013-10-17 2020-08-31 Vertex Pharmaceuticals Incorporated Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk
AP2017009724A0 (en) 2014-07-17 2017-01-31 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
WO2017214286A1 (en) * 2016-06-07 2017-12-14 Northwestern University Substituted 4-(1-pyrrolidinyl)pyrimidine compounds as dimerization inhibitors of neuronal nitric oxide synthase
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
RU2732297C2 (ru) * 2018-11-14 2020-09-15 Общество с ограниченной ответственностью "Гурус БиоФарм" Производные нестероидных противовоспалительных средств

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339875A (ja) * 1986-08-05 1988-02-20 Nissin Food Prod Co Ltd ピリミジン誘導体
ATE163647T1 (de) * 1993-08-26 1998-03-15 Ono Pharmaceutical Co 4-aminopyrimidin derivate

Also Published As

Publication number Publication date
GB9919686D0 (en) 1999-10-20
HK1025952A1 (en) 2000-12-01
GB2338957A8 (en) 2000-01-26
NO993996D0 (no) 1999-08-19
EP0968206B1 (de) 2006-11-15
SK113599A3 (en) 2000-07-11
CN1252799A (zh) 2000-05-10
DK0968206T3 (da) 2007-03-26
JP2002515058A (ja) 2002-05-21
GB2338957B (en) 2001-08-01
AU6174998A (en) 1998-09-09
SK286779B6 (sk) 2009-05-07
EP0968206B8 (de) 2007-01-24
DE69836422T2 (de) 2007-06-14
NO993996L (no) 1999-10-18
PT968206E (pt) 2007-02-28
KR20000075615A (ko) 2000-12-26
NO321664B1 (no) 2006-06-19
CA2281545C (en) 2007-04-24
NZ337861A (en) 2001-02-23
RU2241708C2 (ru) 2004-12-10
WO1998037079A1 (en) 1998-08-27
CZ2008628A3 (cs) 2016-09-29
JP4495257B2 (ja) 2010-06-30
PL335235A1 (en) 2000-04-10
CN1100777C (zh) 2003-02-05
ES2277382T3 (es) 2007-07-01
CA2281545A1 (en) 1998-08-27
IL131475A0 (en) 2001-01-28
GB2338957A (en) 2000-01-12
EP1754703A3 (de) 2007-02-28
EP0968206A1 (de) 2000-01-05
AU732969B2 (en) 2001-05-03
DE69836422D1 (de) 2006-12-28
EP1754703A2 (de) 2007-02-21

Similar Documents

Publication Publication Date Title
ATE345339T1 (de) N-heterocyclische derivate als nos inhibitoren
ATE256681T1 (de) N-heterozyklische derivate als nos inhibitoren
DE60101000D1 (de) N-heterocyclische derivate als nos inhibitoren
ATE353216T1 (de) 1-substituierten imidazol derivaten als nos inhibitoren
ATE177078T1 (de) Amidino-derivate als no-synthetase inhibitoren
DE60003949D1 (de) 5-aryl-1h-1,2,4 triazolverbindungen als cyclooxygenase -2 inhibitoren und dieseenthaltende pharmazeutische zusammensetzungen
ATE300541T1 (de) Pyrazolopyridinderivate
ATE498600T1 (de) Inden derivate als pharmazeutika
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel
SE9904128D0 (sv) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0968206

Country of ref document: EP

REN Ceased due to non-payment of the annual fee